Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

@article{Clotet2007EfficacyAS,
  title={Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.},
  author={Bonaventura Clotet and Nicholas C Bellos and Jean-Michel Molina and David Jamie Cooper and Jean-Christophe Goffard and Adriano Lazzarin and Andrej Woehrmann and Christine Katlama and Timothy J. Wilkin and Richard Haubrich and Calvin J Cohen and Charles E Farthing and Dushyantha S Jayaweera and Martin Markowitz and Peter J Ruane and Sabrina Spinosa-Guzman and Eric A Lefebvre},
  journal={Lancet},
  year={2007},
  volume={369 9568},
  pages={1169-78}
}
BACKGROUND The continuing, randomised, multinational, phase IIB POWER 1 and 2 studies aim to evaluate efficacy and safety of darunavir in combination with low-dose ritonavir in treatment-experienced HIV-1-infected patients. We did a pooled subgroup analysis to update results at week 48 for patients receiving the recommended dose of darunavir-ritonavir compared with those receiving other protease inhibitors (PIs). METHODS After 24-week dose-finding phases and primary efficacy analyses… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
162 Extracted Citations
18 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 162 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 18 references

Effi cacy and safety of TMC 114 / ritonavir in treatment - experienced HIV patients : 24 - week results of POWER 1

  • R Haubrich, D Berger, P Chiliade
  • AIDS
  • 2007

Durability of viral load suppression with darunavir/ritonavir in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis

  • NC Bellos, R Falcon, A. Hill
  • Toronto: 44th Annual Meeting of the Infectious…
  • 2006

Phenotypic and genotypic determinants of TMC114 (darunavir) resistance: POWER 1, 2 and 3 pooled analysis

  • S De Meyer, T Vangeneugden, E Lefebvre
  • Glasgow: 8th International Congress on Drug…
  • 2006

Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

  • M Nelson, K Arasteh, B Clotet
  • 2006

Similar Papers

Loading similar papers…